PARP inhibitors in ovarian cancer

被引：5

作者：

Goldlust, Ian S. ^{[1
]}

Guidice, Elena ^{[1
]}

Lee, Jung-min ^{[1
,2
]}

机构：

[1] NCI, Womens Malignannes Branch, Ctr Canc Res, NIH, Bethesda, MD USA

[2] 10 Ctr Dr,Bldg 10,Room 6B12, Bethesda, MD 20892 USA

来源：

SEMINARS IN ONCOLOGY | 2024年 / 51卷 / 1-2期

关键词：

Epithelial ovarian cancer; Homologous recombination deficiency; BRCA mutation; PARP inhibitor; PLATINUM-BASED CHEMOTHERAPY; PHASE-III TRIAL; OLAPARIB MONOTHERAPY; DOUBLE-BLIND; NONPLATINUM CHEMOTHERAPY; MAINTENANCE THERAPY; SEROUS OVARIAN; OPEN-LABEL; RUCAPARIB; CARCINOMA;

D O I：

10.1053/j.seminoncol.2024.01.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly-ADP-ribose polymerase inhibitors (PARPis) were first approved for the treatment of epithelial ovarian cancer (EOC), where as a maintenance therapy they transformed clinical management of this disease in both patients with and without homologous recombination deficiency. In this review, we provide a historical overview of PARPi use in EOC and discuss recent updates on overall survival data, highlighting their impact on regulatory approvals. We explore their potential as combination regimens with antiangiogenic and cell-cycle checkpoint inhibitors, as well as other small molecule inhibitors, to overcome resistance mechanisms and enhance therapeutic efficacy, providing a future perspective on the use of PARPis in EOC treatment. Published by Elsevier Inc.

引用

页码：45 / 57

页数：13

共 46 条

[1]

[Anonymous], Cancer of the Ovary - Cancer Stat Facts

[2] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[3] Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer [J].

Chiappa, M. ;

Guffanti, F. ;

Bertoni, F. ;

Colombo, I. ;

Damia, G. .

DRUG RESISTANCE UPDATES, 2021, 55

[4] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].

Coleman, R. L. ;

Fleming, G. F. ;

Brady, M. F. ;

Swisher, E. M. ;

Steffensen, K. D. ;

Friedlander, M. ;

Okamoto, A. ;

Moore, K. N. ;

Ben-Baruch, N. Efrat ;

Werner, T. L. ;

Cloven, N. G. ;

Oaknin, A. ;

DiSilvestro, P. A. ;

Morgan, M. A. ;

Nam, J. -H. ;

Leath, C. A., III ;

Nicum, S. ;

Hagemann, A. R. ;

Littell, R. D. ;

Cella, D. ;

Baron-Hay, S. ;

Garcia-Donas, J. ;

Mizuno, M. ;

Bell-McGuinn, K. ;

Sullivan, D. M. ;

Bach, B. A. ;

Bhattacharya, S. ;

Ratajczak, C. K. ;

Ansell, P. J. ;

Dinh, M. H. ;

Aghajanian, C. ;

Bookman, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415

[5] OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA [J].

Coleman, Robert L. ;

Oza, Amit ;

Lorusso, Domenica ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert ;

Amenedo Gancedo, Margarita ;

Fong, Peter ;

Goh, Jeffrey ;

O'Malley, David ;

Goble, Sandra ;

Maloney, Lara ;

Ledermann, Jonathan .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 :A3-A5

[6] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Coleman, Robert L. ;

Oza, Amit M. ;

Lorusso, Domenico ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne, I ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert W. ;

Amenedo Gancedo, Margarita ;

Fong, Peter C. ;

Goh, Jeffrey C. ;

O'Malley, David M. ;

Armstrong, Deborah K. ;

Garcia-Donas, Jesus ;

Swisher, Elizabeth M. ;

Floquet, Anne ;

Konecny, Gottfried E. ;

McNeish, lain A. ;

Scott, Clare L. ;

Cameron, Terri ;

Maloney, Lara ;

Isaacson, Jeff ;

Goble, Sandra ;

Grace, Caroline ;

Harding, Thomas C. ;

Raponi, Mitch ;

Sun, James ;

Lin, Kevin K. ;

Giordano, Heidi ;

Ledermann, Jonathan A. .

LANCET, 2017, 390 (10106) :1949-1961

[7] Mechanisms of PARP inhibitor sensitivity and resistance [J].

D'Andrea, Alan D. .

DNA REPAIR, 2018, 71 :172-176

[8] Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial [J].

DiSilvestro, Paul ;

Banerjee, Susana ;

Colombo, Nicoletta ;

Scambia, Giovanni ;

Kim, Byoung-Gie ;

Oaknin, Ana ;

Friedlander, Michael ;

Lisyanskaya, Alla ;

Floquet, Anne ;

Leary, Alexandra ;

Sonke, Gabe S. ;

Gourley, Charlie ;

Oza, Amit ;

Gonzalez-Martin, Antonio ;

Aghajanian, Carol ;

Bradley, William ;

Mathews, Cara ;

Liu, Joyce ;

McNamara, John ;

Lowe, Elizabeth S. ;

Ah-See, Mei-Lin ;

Moore, Kathleen N. .

OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (01) :25-27

[9] Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy [J].

Domchek, Susan M. ;

Aghajanian, Carol ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Loman, Niklas ;

Robertson, Jane D. ;

Mann, Helen ;

Kaufman, Bella .

GYNECOLOGIC ONCOLOGY, 2016, 140 (02) :199-203

[10] Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial [J].

Frenel, J. S. ;

Kim, J. W. ;

Aryal, N. ;

Asher, R. ;

Berton, D. ;

Vidal, L. ;

Pautier, P. ;

Ledermann, J. A. ;

Penson, R. T. ;

Oza, A. M. ;

Korach, J. ;

Huzarski, T. ;

Pignata, S. ;

Colombo, N. ;

Park-Simon, T. W. ;

Tamura, K. ;

Sonke, G. S. ;

Freimund, A. E. ;

Lee, C. K. ;

Pujade-Lauraine, E. .

ANNALS OF ONCOLOGY, 2022, 33 (10) :1021-1028

← 1 2 3 4 5 →